Patents Examined by Bin Shen
  • Patent number: 11453858
    Abstract: In some aspects, described herein are cell culture media that are useful for in vitro culture of mammalian cells. The culture media contain a variety of small organic compounds that are found in normal adult human blood. Also described are methods of using the culture media for a variety of purposes. Also described are methods of treating cancer.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: September 27, 2022
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: David M. Sabatini, Jason Cantor
  • Patent number: 11448645
    Abstract: Cultivation and/or test-system comprising at least two cultivation spaces combined in a microparticle, wherein the sperically shaped microparticle comprises, (i) a first cultivation space in the center core of said spherically shaped microparticle, (ii) a second cultivation space in the wall surrounding the core of said microparticle, (iii) wherein the wall surrounding the core allows for the exchange of molecules as, salts, nutrients, peptides, chemicals and other compounds in order for the cells in the first cultivation space to interact with the cells in second cultivation space and vice versa. In the test system, the cells are co-cultivated and the microparticles are then selected based on the phenotype of the cells in the first or second cultivation space.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: September 20, 2022
    Assignee: Biomillenia SAS
    Inventors: Dirk Loeffert, Aleksander Dajkovic, Thomas Duboys
  • Patent number: 11447638
    Abstract: The present invention provides di-substituted acetalanthraquinone-based compounds of the Formulae (l)-(IV) that are useful for cellular staining and for light-based detection of biological material, e.g. fluorescence-based detection of biological material. These compounds may be used in hydrolysed or non-hydrolysed form. Also provided is a fluorescent complex that comprises a nucleic acid and an acetalanthraquinone-based compound of the invention; and a method of staining a biological sample comprising cells or other biological material containing nucleic acid, which method comprises contacting the biological sample with an acetalanthraquinone-based compound of the invention. In the Formulae (l)-(IV), A and B are each independently of formula —RaCH2CH(ORb)2; or one of A and B is of formula —RaCH2CH(ORb)2 and the other one is of formula: —NRb2.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: September 20, 2022
    Assignee: BIOSTATUS LIMITED
    Inventors: Paul James Smith, Rachel Jane Errington, Laurence Hylton Patterson, Klaus Pors, Laura Cosentino
  • Patent number: 11439691
    Abstract: The present invention relates to an aqueous solution comprising burlulipase which is characterized in that it contains calcium ions. In particular, it also relates to corresponding pharmaceuticals. Such pharmaceuticals are suitable for the treatment of exocrine pancreatic insufficiency. These pharmaceuticals are particularly suitable for treating patients having cystic fibrosis and in pediatrics. Another aspect of the present invention relates to container-packaged solutions and pharmaceuticals as mentioned above, which are containers produced by the blow-fill-seal method, and to methods for producing such packaged solutions and pharmaceuticals.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: September 13, 2022
    Assignee: NORDMARK PHARMA GMBH
    Inventors: Richard Fuhrherr, Annika Müller-Lucks, Katharina Rützel, Jan Lüdemann, Martin Werner
  • Patent number: 11442063
    Abstract: Provided herein are compounds that are broad-spectrum protein kinase binding agents, detectable tracers comprising such compounds, and method of use thereof for the detection of protein kinases.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: September 13, 2022
    Assignee: Promega Corporation
    Inventors: Cesear Corona, Poncho Meisenheimer, Matthew Robers, James Vasta
  • Patent number: 11442072
    Abstract: The present disclosure relates to a method for measuring aggregation of low-density lipoprotein (LDL). The susceptibility of LDL to aggregate is an important factor regarding prognosis, diagnosis and surveillance of atherosclerotic cardiovascular diseases and cardiometabolic diseases, such as type 2 diabetes and related conditions, at various stages of their development. Also provided are methods of treatment of such diseases in subjects in need thereof.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: September 13, 2022
    Assignee: Jenny and Antti Wihuri Foundation
    Inventors: Katariina Öörni, Maija Ruuth, Petri Kovanen
  • Patent number: 11419830
    Abstract: The present invention is directed, in part, to methods of treating Epidermolysis Bullosa (EB) in a subject in need thereof, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of a of Coenzyme Q10 (CoQ10) to the subject.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: August 23, 2022
    Assignee: Berg LLC
    Inventors: Niven Rajin Narain, Rangaprasad Sarangarajan, Michael Andrew Kiebish
  • Patent number: 11414691
    Abstract: Provided are an organoid having a metastatic property when transplanted into an immunocompetent non-human animal of the same species, a cell strain having a metastatic property when transplanted into an immunocompetent non-human animal of the same species, and a non-human animal including the organoid or the cell strain.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: August 16, 2022
    Assignee: National University Corporation Kanazawa University
    Inventors: Masanobu Oshima, Mizuho Nakayama, Eri Sakai
  • Patent number: 11401502
    Abstract: An object of the present invention is to provide highly proliferative mesenchymal stem cells (MSCs) useful for the large-scale and rapid production of a cell preparation, and a cell population comprising the mesenchymal stem cells. According to the present invention, there is provided a cell population comprising mesenchymal stem cells derived from the fetal appendage, wherein, in the cell population, the proportion of CD105+ mesenchymal stem cells is 50% or more, the proportion of CD200+ mesenchymal stem cells is less than 10%, and the proportion of CD106+ mesenchymal stem cells is less than 5%.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: August 2, 2022
    Assignee: KANEKA CORPORATION
    Inventors: Masahiro Hayashi, Yuta Kita, Nobuyoshi Umeda
  • Patent number: 11401501
    Abstract: The present invention provides a method for culturing organoids, the method comprising: a) disassociating unprocessed organoids to produce a cell suspension; b) sieving the cell suspension through a cell strainer to retain a sieved cell suspension containing cells of about 10 ?m to about 1 mm in diameter; and c) seeding cells of the sieved cell suspension into a bioreactor in a cell culture medium comprising an extracellular support matrix.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: August 2, 2022
    Assignee: CELLESCE LIMITED
    Inventors: Marianne J. Ellis, Julian Chaudhuri, Trevor Clive Dale
  • Patent number: 11396642
    Abstract: Provided are a tumour immunogen, a preparation method therefore, and an application. After localised sequential cooling-heating treatment is performed on tumour tissue and/or cells, the tumour tissue and/or cells release a large amount of tumour immunogen heat shock protein 70. The obtained tumour immunogen can activate the body's tumour immune system, to convert immunosuppressive cells into mature dendritic cells, thereby increasing immunogen presentation, and activating tumour immunity.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: July 26, 2022
    Assignee: MAGI COMPANY LTD
    Inventors: Xuemin Xu, Ping Liu, Aili Zhang, Jingfeng Bai, Jianqi Sun, Jincheng Zou
  • Patent number: 11384334
    Abstract: Provided are: a polymer gel for a medium, and a medium in which the stiffness of the polymer gel can be easily and reversibly changed and the shape of cells can be controlled according to the stiffness of the gel; and a method for culturing cells using the medium. The polymer gel for a medium contains a solvent and a crosslinked structure that is crosslinked by reversible bonds. The stiffness of the polymer gel for a medium can be easily and reversibly changed. Accordingly, when the polymer gel for a medium according to the present invention is used, cell morphology and function can be reversibly controlled according to the stiffness of the gel.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: July 12, 2022
    Assignees: Osaka University, Kyoto University
    Inventors: Akira Harada, Yoshinori Takashima, Masaki Nakahata, Motomu Tanaka, Marcel Hoerning
  • Patent number: 11376593
    Abstract: Systems and methods for sorting T cells are disclosed. Autofluorescence data is acquired from individual cells. An activation value is computed using one or more autofluorescence endpoints as an input. The one or more autofluorescence endpoints includes NAD(P)H shortest fluorescence lifetime amplitude component (?1).
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 5, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Melissa Caroline Skala, Alexandra Jule Walsh
  • Patent number: 11378570
    Abstract: A cytotoxicity method for medical devices that has equivalent sensitivity, and greater efficiency compared to the colony formation assay (CFA) direct contact method is developed. The quantitative, direct contact cytotoxicity test method uses Mouse lymphoma TK or human lymphoblastoid TK6 suspension cells for medical device safety assessment. The advantages of using the suspension cell assay over adherent V79-4 cells is that this approach is quantitative, automated, not susceptible to potential mechanical damage imparted by the overlying test materials, and avoids issues related to non-adherence of cells to the test material which might impact the interpretation of test results.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: July 5, 2022
    Assignee: Alcon Inc.
    Inventors: Xuemei Liu, Fan Zhang, Denise P. Rodeheaver, Ann Marie Wright, Charlon Tolliver, Jamie Michaelis Walker, Robert Edward Rose, Stephen Paul Shannon, Jeffrey Charles White
  • Patent number: 11377634
    Abstract: Disclosed herein is an integrated assay system that can be used, for example, to monitor and screen cells in 3D culture. This system involves a 3D cell growth medium made from a yield stress material that allows cells to be deposited, e.g. by 3D printing, samples to be taken, and the extracellular environment manipulated.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: July 5, 2022
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Wallace Gregory Sawyer, Thomas Ettor Angelini, Steven C. Ghivizzani, C. Parker Gibbs
  • Patent number: 11363820
    Abstract: The present invention provides a screening method for selecting plant symbiotic microorganisms enabling plant growth under abiotic stress and/or biotic stress, a microbial mixture of microorganisms which are selected from nature by the method and enables a plant to grow under salinity stress and/or hyperosmotic stress in symbiosis with the plant. Specifically, the present invention provides a screening method for selecting plant symbiotic microorganisms, comprising a first screening step of allowing at least one plant to grow for a predetermined period of time while being partially soaked in a solution containing a microbial mixture under abiotic stress and/or biotic stress, and collecting microorganisms adhering to grown plant to thereby select out the microorganisms as plant symbiotic microorganisms enabling plant growth under the stress.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: June 21, 2022
    Assignee: SEKISUI CHEMICAL CO., LTD.
    Inventor: Seigo Ono
  • Patent number: 11365388
    Abstract: Provided is a method of producing a novel microorganism having a minimal genome. In particular, provided are a method of producing a novel microorganism having a smaller genome size than a wild-type, the method including the step of culturing the microorganism in a medium containing LB broth with stepwise decreasing concentrations of the LB broth; and a novel microorganism having a smaller genome size than a wild-type, produced by the above method. Despite the small genome size, the novel microorganism of the present disclosure may have a high growth rate, pyruvate production capacity, and protein translation efficiency thereby being usefully applied to industry such as production of recombinant proteins or pyruvate.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: June 21, 2022
    Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Sun-Chang Kim, Byung-Kwan Cho, Donghui Choe, Bong Hyun Sung, Jun Hyoung Lee
  • Patent number: 11345886
    Abstract: The presently disclosed subject matter relates, in general, to the identification, isolation, and use of a population of stem cells isolated from umbilical cord blood, peripheral blood and/or other sources and that are referred to herein as Small Mobile Stem cells (short: SMS). More particularly, the presently disclosed subject matter relates to isolating said SMS stem cells and employing the same, optionally after in vitro manipulation, to treat tissue and/or organ damage in a subject in need thereof.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: May 31, 2022
    Assignee: SMSBIOTECH, INC.
    Inventor: Abdulkader Rahmo
  • Patent number: 11332712
    Abstract: A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: May 17, 2022
    Assignee: UNIVERSITY OF MIAMI
    Inventor: Tan Ince
  • Patent number: 11332711
    Abstract: Described herein are compositions and methods to cryopreserve sporozoites. In some aspects, the method can include the step of placing harvested salivary glands containing sporozoites into an insect-based medium.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: May 17, 2022
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: John H. Adams, Alison Elizabeth Roth